Instrument Inactif

Autres langues ACLS THER Nasdaq

Actions

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

14/05	Transcript : Aclaris Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-14-2026 09:35 AM
07/05	Aclaris Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Comp Growth Benchmark
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 2500 Growth Benchmark
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 2000 Growth Benchmark
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 3000E Growth Benchmark
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index
29/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 3000 Growth Benchmark
22/06	Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to S&P Pharmaceuticals Select Industry Index
28/05	Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
08/05	Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
08/05	Aclaris Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Aclaris: Q1 Earnings Snapshot
07/05	Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
28/04	Aclaris Therapeutics says positive full top line results from Phase 1a clinical trial of ATI-055
28/04	Aclaris Therapeutics : ATI-052 full SAD/MAD results + ATI-2138 update (44ce59)
28/04	Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
28/04	Aclaris Therapeutics Announces Positive Full Top Line First-In-Human Results from Phase 1A Healthy Volunteer Clinical Trial of ATI-052 and Lichen Planus as Lead Indication for ATI-2138
28/04	Aclaris Therapeutics Insider Sold Shares Worth $1,359,000, According to a Recent SEC Filing
27/04	Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
09/04	Cardiff Oncology, Inc. Announces Management Appointments
08/04	Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
30/03	Aclaris Therapeutics - Results Presented at 2026 American Academy of Dermatology Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
27/03	Aclaris Therapeutics, Inc. Provides Additional Results from Phase 2A Trial of ATI-2138
27/03	Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
20/03	Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting